Zhenyu Zhou, Zheng Chen, Qianlei Zhou, Shiyu Meng, Juanyi Shi, Sintim Mui, Hai Jiang, Jianhong Lin, Gui He, Wenbin Li, Jianlong Zhang, Jie Wang, Chuanchao He, Yongcong Yan, Zhiyu Xiao
Both lysine and arginine methyltransferases are thought to be promising therapeutic targets for malignant tumors, yet how these methyltransferases function in malignant tumors, especially hepatocellular carcinoma (HCC), has not been fully elucidated. Here, we reported that SMYD4, a lysine methyltransferase, acts as an oncogene in HCC. SMYD4 was highly upregulated in HCC and promoted HCC cell proliferation and metastasis. Mechanistically, PRMT5, a well-known arginine methyltransferase, was identified as a SMYD4-binding protein...
March 4, 2024: Cancer Science